| 6.01 0.16 (2.74%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.46 | 1-year : | 9.51 |
| Resists | First : | 7.24 | Second : | 8.14 |
| Pivot price | 6.44  |
|||
| Supports | First : | 5.78 | Second : | 4.8 |
| MAs | MA(5) : | 5.98 |
MA(20) : | 6.78 |
| MA(100) : | 6.49 |
MA(250) : | 4.94 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 4.7 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 8.32 | Low : | 1.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ STTK ] has closed above bottom band by 24.7%. Bollinger Bands are 7.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.23 - 6.27 | 6.27 - 6.31 |
| Low: | 5.72 - 5.77 | 5.77 - 5.81 |
| Close: | 5.93 - 6.01 | 6.01 - 6.08 |
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Thu, 17 Sep 2026
Shattuck Labs Q2 2026 Earnings: Clinical-Stage Balance Sheet in Focus as EPS Meets Estimates - careplusvn.com
Wed, 02 Sep 2026
Shattuck Labs Announces Participation in Upcoming September Investor Conferences - Investing News Network
Wed, 02 Sep 2026
Shattuck Labs (STTK) Gains 2.81% to $7.06 as Momentum Builds Above Key Support - BPI Bear Correction - careplusvn.com
Tue, 01 Sep 2026
Shattuck Labs Stock: A Receptor-Side Bet On The TL1A Boom (NASDAQ:STTK) - Seeking Alpha
Mon, 24 Aug 2026
What Shattuck Labs Stock Topped the Market on Monday - Yahoo Finance
Thu, 20 Aug 2026
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 100 (M) |
| Held by Insiders | 6.776e+007 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 7,800 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.214e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 570.5 % |
| Return on Equity (ttm) | -24.5 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -35.65 |
| EBITDA (p.s.) | -3.47636e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.17 |
| Price to Cash Flow | 5.2 |
| Dividend | 0 |
| Forward Dividend | 6.01e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|